Analysis of GP73 in patients with HCC as a function of anti-cancer treatment.
Analysis of GP73 in patients with HCC as a function of anti-cancer treatment.
复制标题
DOI：
10.3233/cbm-2010-0190
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Mehta A
中科院分区：
文献类型：
--
作者：
Hann HW;Wang M;Hafner J;Long RE;Kim SH;Ahn M;Park S;Comunale MA;Block TM;Mehta A
在这项研究中，我们检测了9名患者血清中高尔基蛋白73(GP73)的水平作为抗肝癌治疗的一种功能。虽然数字很小，但观察到了一个明显的趋势。保持无肿瘤状态的患者(治疗后长达6年)在治疗后第一个可用时间点显示GP73降低。相比之下，治疗后GP73水平高的患者在5年内都有复发。这些数据是初步的，但戏剧性地暗示，该标记物可能在监测肝细胞癌患者中有价值，并且即使在存在小的、无法检测的肿瘤时也可能升高。
In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-treatment) showed reductions in GP73 at the first time point available post-treatment. In contrast, patients who had high levels GP73 post treatment all had re-occurrence within a 5 year period. These data are preliminary but dramatically imply that this marker may have value in the monitoring of HCC patients and may be elevated even when small, undetectable tumors are present.